drugset / Trial / NCT05456256
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multicenter, open label, phase II trial with 90 patients to be enrolled in the United States.
Timeline
- Start
- 2023-03-01
- Primary completion
- 2026-12
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2,2'-DITHIODIETHANESULFONIC ACID | Small molecule | 18.4 g | Intravenous |
| Background | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |